Neurocrine Biosciences, Inc. (NBIX) Q2 2023 Earnings Call Transcript

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q2 2023 Earnings Conference Call August 1, 2023 8:00 AM ET

Company Participants

Todd Tushla – VP, IR

Kevin Gorman – CEO

Matt Abernethy – CFO

Eiry Roberts – Chief Medical Officer

Eric Benevich – Chief Commercial Officer

Kyle Gano – Chief Business Development & Strategy Officer

Conference Call Participants

Paul Matteis – Stifel

Tazeen Ahmad – Bank of America

Anupam Rama – JPMorgan

Phil Nadeau – TD Cowen

Jay Olson – Oppenheimer

Leon Wang – Barclays

Marc Goodman – Leerink

Brian Abrahams – RBC Capital Markets

Brian Skorney – Baird

Jeff Hung – Morgan Stanley

Myles Minter – William Blair

Danielle Brill – Raymond James

Evan Seigerman – BMO

Laura Chico – Wedbush Securities

Sumant Kulkarni – Canaccord

David Amsellem – Piper Sandler

Ash Verma – UBS

Yatin Suneja – Guggenheim

Uy Ear – Mizuho


Good day, everyone, and welcome to today’s Neurocrine Biosciences Reports Second Quarter Results. [Operator Instructions] It is now my pleasure to turn today’s program over to Todd Tushla, Vice President of Investor Relations.

Todd Tushla

Good morning, and welcome to Neurocrine’s second quarter 2023 earnings call. Today, I’m joined by Kevin Gorman, our Chief Executive Officer; Matt Abernethy, our Chief Financial Officer; Eiry Roberts, our Chief Medical Officer; Eric Benevich, our Chief Commercial Officer; and Kyle Gano, our Chief Business Development and Strategy Officer.

During today’s call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. After prepared remarks, we will jump into Q&A.

With that, I’ll turn the call over to Kevin Gorman.

Kevin Gorman

Thank you, Todd, and good morning, everyone. It’s a pleasure to be here this morning. We’ve had a very strong first

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *